According to Politico, Western New York Congressman Chris Collins will continue under the eye of the House Ethics Committee…but that committee is not moving ahead with a full-scale investigation into Collins’ dealings with an Australian biotech company.
The Office of Congressional Ethics, an independent watchdog group, unanimously recommended a full investigation of Collins’ investments into Innate Immunotherapeutics Limited. Collins has invested at least $6 million into the firm and sits on its board. He recommended the stock to former HHS Secretary Tom Price, plus other lawmakers in Buffalo. Price made more than $225,000 trading in the stock. There are suspicions that Collins might have shared insider information.
Collins maintains he has done nothing wrong, and followed all rules and ethical guidelines for his personal investments.